Cranial Manipulation Modulates Cholinergic Pathway Gene Expression in an Animal Model of Age-related Cognitive Decline

Ramu Anandakrishnan (ramu@vt.edu)
Edward Via College of Osteopathic Medicine
https://orcid.org/0000-0003-0422-3984

Hope Tobey
Edward Via College of Osteopathic Medicine - Virginia Campus: Edward Via College of Osteopathic Medicine

Steven Nguyen
Edward Via College of Osteopathic Medicine - Virginia Campus: Edward Via College of Osteopathic Medicine

Osscar Gonzalez Sandoval
Edward Via College of Osteopathic Medicine - Virginia Campus: Edward Via College of Osteopathic Medicine

Bradley G. Klein
Virginia Tech: Virginia Polytechnic Institute and State University

Blaise M. Costa
Edward Via College of Osteopathic Medicine - Virginia Campus: Edward Via College of Osteopathic Medicine

Short report

Keywords: Osteopathic Cranial Manipulative Medicine, OCMM, Dementia, Alzheimer's disease, Transcriptome, Gene expression, Neuronal pathway

DOI: https://doi.org/10.21203/rs.3.rs-76112/v1

License: This work is licensed under a Creative Commons Attribution 4.0 International License. Read Full License
Abstract

Age dependent dementia is a devastating disorder afflicting the growing older population around the world. Although pharmacological agents improve symptoms of dementia, age related co-morbidities combined with adverse effects often outweigh their clinical benefits. Therefore, non-pharmacological therapies are being investigated as an alternative. Randomized controlled trials and observational studies have shown promising results for cranial manipulation as a treatment for dementia and other nervous system disorders. In this study we examine the effect of osteopathic cranial manipulative medicine (OCMM) on gene expression, in an animal model for age-related cognitive decline (aged rats). We found that OCMM significantly affected the expression of 36 genes in the neuronal pathway (False Discovery Rate (FDR) < 0.004). The top five neuronal genes with the largest fold-change (Slc5a7, Chat, Slc18a3, Adcy5 and Cacna2d2, >2-fold change, FDR<0.004) are part of the cholinergic neurotransmission mechanism, which is known to affect cognitive function. Slc5a7, the highest overexpressed neuronal gene (3-fold change) encodes a sodium and chloride ion-dependent high-affinity transporter that mediates choline uptake for acetylcholine synthesis in cholinergic neurons. This is the pathway enhanced by the clinically used Alzheimer's disease drug Donepezil, which selectively inhibits acetylcholinesterase, an enzyme that catalyzes endogenous acetylcholine degradation. In addition, 40% of significant differentially expressed (SDE) genes (FDR<0.004), have been previously implicated in neurological disorders. Overall, SDE genes and their role in central nervous system signaling pathways suggest a connection to previously reported OCMM induced behavioral and biochemical changes in rat models of age-dependent dementia. Further investigation in this direction will provide a better understanding of the molecular mechanisms of OCMM and its potential in clinical applications. With clinical validation, OCMM could represent a much needed low-risk adjunct treatment for age-related dementia including Alzheimer's disease.

Main Text

Dementia is a progressive neurodegenerative disease primarily afflicting a rapidly growing older population[1], and one of the primary causes of disability and dependency in this population[2]. Over 50 million people suffer from dementia worldwide, with approximately 10 million new cases per year[2]. Alzheimer’s disease contributes to 60–80% of dementia cases[3]. Although there are treatments to manage its symptoms, currently there is no cure for dementia or a treatment for halting its progression or delaying its onset.

Two classes of drugs have been approved for treating dementia symptoms: acetylcholinesterase (AChE) inhibitors for mild to moderate symptoms and an N-methyl-D-aspartate receptor (NMDAR) antagonist for moderate to severe symptoms[4–6]. Although these drugs have been effective in managing the symptoms in the short-term (3–6 months), their longer term benefits are questionable[7–9]. Combined with age-related comorbidities, the undesirable side effects of these drugs often outweigh their benefits.
OCMM as a potential adjunct treatment for age-related dementia

Osteopathic cranial manipulative medicine (OCMM) represents a potential low-risk adjunct treatment to minimize the dosage or use of pharmaceutical treatments. Randomized controlled trials have shown that cranial manipulation can reduce pain in patients with fibromyalgia[10, 11] and lateral epicondylitis[12]. Observational studies have shown a reduction in symptoms associated with dementia[13] and multiple sclerosis[14]. Studies have also shown that OCMM affects cerebral blood flow[15, 16], tissue oxygenation in prefrontal lobes[17], brain cortex electrical activity[18] and reduction in Amyloid beta (Aβ) protein levels[19, 20]. How might OCMM produce these effects? In vivo and in vitro studies have shown that mechanical stress can affect cellular activity and growth in neuronal cells[21–23]. Simulated mechanical stimuli, similar to sub-traumatic cranial pressure, was shown to induced cellular activity in neural cell cultures by modulating ion channels[21]. Mechanical compression of neural stem cells was shown to contribute to neurogenesis and neuronal migration[22]. Compression of the cerebral cortex simulated by epidural bead implanted in rats, showed a rapid increase in NMDA receptor concentration and postsynaptic activity[23].

In a previous study we showed that OCMM treatment improves spatial memory in aged rats (an animal model for age-related cognitive decline), as measured by the Morris water maze assay[19]. To identify a possible molecular mechanism for the effect of OCMM, in this study, we analyzed gene RNA expression in prefrontal cortex tissue samples from OCMM treated aged rats and from untreated (control) rats. Transcriptional regulation is crucial for organogenesis, functional adaptation, and regeneration in adult tissues and organs[24]. Study of the transcriptome can provide insights into changes that affect subsequent proteins synthesis, trafficking and cellular activity.

OCMM significantly affects gene expression

RNA from tissue samples from the prefrontal cortex of three OCMM treated rats and three untreated control rats were extracted and sequenced as described in Methods. The number of reads from RNA sequencing ranged from 58–74 million with average read lengths of 73–75, across the six samples. Ninety six percent of the reads were successfully mapped to the rat genome. See Table S1 for a detailed breakdown of read mapping.

We compared gene expression levels calculated from the sequencing data for OCMM treated and untreated animals. The comparison showed that 688 genes were differentially expressed with FDR < 0.01, of which 426 had FDR < 0.004 (Fig. 1a). For the following analysis we focus on the 426 genes with FDR < 0.004, which we refer to as significant differentially expressed (SDE) genes. Of these 426 SDE genes, 314 were over expressed and 112 under expressed.

Neuronal system pathways were over-represented in SDE genes
The Reactome database contains a list of genes that have been associated with specific pathways[25]. We compared the distribution of Reactome top-level pathways associated with all genes that were sequenced, to the distribution of these pathways for SDE genes. Genes associated with neuronal system pathways were most significantly over-represented in the SDE gene set with FDR = 3E-14 (Fig. 1b). Thirty six (8%) of 426 SDE genes were associated with neuronal pathways (Fig. 1c), compared to 343 (2%) of all 14278 genes that were sequenced. The signal transduction pathway was also over-represented with FDR = 1E-5, while the gene expression pathway was under-represented with FDR = 5E-5. In addition, pathways for protein metabolism, cell cycle, and response to stress were under-represented and the muscle contraction pathway over-represented, with FDR < 0.01.

**Cholinergic neurotransmission pathways were affected by SDE genes**

Of the 36 SDE genes in the neuronal system pathway, 27 of them were over-expressed and 9 of them under-expressed in OCMM treated animals compared to untreated animals (Fig. 1c). Twenty of the 36 neuronal SDE genes were associated with signal transmission chemical synapses, 13 with potassium channels and 8 with protein-protein interaction at synapses.

The five genes with the largest fold change, Slc5a7, Chat, Slc18a3, Adcy5 and Cacna2d2 (Fig. 1c), are part of the acetylcholine (ACh) neurotransmission mechanism (Fig. 2), suggesting increased cholinergic neurotransmission activity in OCMM treated rats. The high affinity choline transporter, Slc5a7 (CHT1), mediates choline uptake at the presynaptic neuron terminal[26, 27]. Choline uptake is a rate limiting step in ACh synthesis and thus ACh mediated neurotransmission[28]. The choline acetylase, Chat, catalyzes the biosynthesis of the ACh neurotransmitter from choline and acetyl-Coenzyme-A[29]. The vesicular ACh transporter, Slc18a3 (VACHT), transports ACh into secretory vesicles for release into the synaptic cleft[30]. Neuronal action potential activates the voltage-gated calcium channel[31], of which Cacna2d2 forms the alpha2/delta2 subunit[32]. The influx of calcium ions, promotes ACh secretion. ACh binding to the acetylcholine receptors (AChR), a G-protein coupled receptor (GPCR), on the postsynaptic neuron, triggers the release of the Ga subunit from the G-protein complex. Ga binds to Adenylate Cyclase 5, Adcy5, activating downstream cAMP signaling pathways, whereas Gai inhibits downstream signaling[33]. The above pathway is targeted by the Alzheimer’s disease drug Donepezil. Donepezil selectively inhibits acetylcholinesterase which catalyzes acetylcholine degradation.

The two most under-expressed genes based on fold change are Chrna3 and Chnb4 (Fig. 1c). These genes code for the α3 and β4 subunits of the pentameric nicotinic ACh gated ion channel receptor (nAChR)[34]. Some studies have suggested nicotine desensitization (inactivation) of nAChR improves memory function in Schizophrenia and Alzheimer’s patients[34–36]. Reduced expression of nAChR, as suggested by the reduced expression of Chrna3 and Chnb4 shown above, could contribute to improved cognitive function.

**SDE genes have been implicated in neurological disorders**
The neurological importance of the genes discussed above is evident from their role in neurological disorders. CHT1 was found to be overexpressed in Alzheimer's disease patients, presumably to compensate for the reduced cholinergic synaptic availability[37]. Polymorphisms in Chat have been associated with increased risk of Alzheimer's disease[38, 39], and reduced Chat expression was found in Parkinson's dementia[40] and Schizophrenia[41] patients. VAChT defects have been implicated in myasthenia syndrome[42] and reduced levels of VAChT have been associated with Alzheimer's disease[43]. Mutations in Cacna2d2 have been linked to epileptic encephalopathy[44]. Adcy5 mutations have been associated with dyskinesia, myokymia, chorea and dystonia[45]. nAChR has been linked to schizophrenia, Alzheimer's and other neurological disorders[34–36].

Overall, 40% of the 426 SDE genes were associated with neurological disorders, with 17% being associated with dementia, 22% with movement disorders, and 28% with psychiatric disorders (Fig. 3). See Table S2 for a list of the 426 genes and references for associated disorders.

This study has shown that OCMM treatment affects the expression of genes associated with neurological pathways and disorders, based on an animal model of age-related dementia. This connection suggests that OCMM could affect the progression of age-related dementia, providing further support for investigating OCMM as a potential adjunct treatment. With clinical validation using robust placebo-controlled double-blind studies, OCMM may offer a much needed low-risk adjunct treatment for age-related cognitive decline.

Materials And Methods

Aged rats

Six 18-month-old F344 male rats were obtained from Charles River Laboratories, Inc, and Envigo. Three of them were randomly selected for OCMM treatment. All rats were provided with normal food and water ad libitum and housed with 12-hour light-dark cycle. All methods were performed in accordance with the relevant guidelines and regulations. All animal experimental procedures and animal housing were approved by the Institutional Animal Care and Use Committee of Virginia Tech (protocol No. 15-099).

OCMM protocol

All OCMM procedures were performed by an experienced Doctor of Osteopathy (H.T.). The protocol consisted of the following steps:

- All rats, including untreated rats, were aestheticized with 1.5% to 3% isoflurane

- For OCMM treatment (CV4 technique), mechanical pressure (3-4 newtons) was applied over the rat’s occiput, medial to the junction of the occiput and temporal bone and inferior to the lambdoid suture to place tension on the dural membrane around the fourth ventricle. This gentle pressure was applied to
resist cranial flexion with the aim of improving symmetry in the cranial rhythmic impulse (CRI), initiating a rhythmic fluctuation of the CSF, and improving mobility of the cranial bones and dural membranes. This rhythmic fluctuation is thought to be primarily due to flexion and extension that takes place at the synchondrosis between the sphenoid and basiocciput. The treatment end point was achieved when the operator identified that the tissues relaxed and improved symmetry or fullness of the CRI was felt (~7 minutes).

- Treatment was performed every day for seven days.

- All rats were euthanized by cervical dislocation after seven days of OCMM treatment.

**Tissue sampling, RNA extraction and sequencing**

Using a rat brain matrix, a 1mm coronal section from the dorsal end prefrontal cortex was sampled from the euthanized rats. RNA was extracted using the PureLink RNA Mini Kit. Extracted RNA were sequenced on the Illumina NextSeq 500 at Virginia Tech's sequencing center. Single-read sequencing was used to investigate highly expressed genes in the well annotated rat genome.

**Differential expression calculation**

The STAR v2.7.3a software package was used to map the fastq format sequencing data. STAR was run with runThreadN=8, outSAMtype=BAM SortedByCoordinate, quantMode=GeneCounts, outSAMstrandField=intronMotif, and outFilterIntronMotifs=RemoveNoncanonicalreads.

The Cufflinks software suite[46] was used to assemble transcriptomes and quantify RNA expression level for each sample. The transcriptomes from all samples were merged into a master transcriptome using Cuffmerge program in Cufflinks. The Cuffdiff program in Cufflinks was then used to calculate significance of differential expression (fold-change, p-value and FDR) between samples from OCMM treated and untreated animals.

**Pathway analysis**

Gene-pathway association data was downloaded from the Reactome database[25]. The 24 top-level Reactome pathway associated with each gene was identified. The percentage of all genes and SDE genes in each top-level pathway was used to calculate the significance of any differences. The chi-squared test statistic was used to calculate p-value. The Benjamini-Hochberg correction for multiple-testing was then applied to calculate FDR.

**Neurological disease association analysis**
A literature search for each of the 426 SDE genes was performed to identify any associations between the gene and neurological disorders.

**Abbreviations**

OCMM: Osteopathic Cranial Manipulative Medicine  
SDE: Significant Differentially Expressed  
CSF: Cerebrospinal Fluid  
FDR: False Discovery Rate  
SDE: Significant differentially expressed  
Ach: Acetylcholinesterase  
Ch: Choline  
AChR: ACh receptors  
AChE: Acetylcholinesterase  
VACHT: Vesicular acetylcholine transporter  
CHT1: Choline transporter-1  
CHT2: Choline transporter-2  
Chat: Choline acetylate  
nAChR: Nicotinic ACh gated ion channel receptor

**Declarations**

*Ethics approval and consent to participate*

All animal experimental procedures and animal housing were approved by the Institutional Animal Care and Use Committee of Virginia Tech (protocol No. 15-099).

*Consent for publication*

Not applicable

*Availability of data and materials*

The datasets supporting the conclusions of this article are available in the Gene Expression Omnibus (GEO) repository, https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE157736.

*Competing interests*

The authors declare that they have no competing interests
Funding

Edward Via College of Osteopathic Medicine (VCOM) Research Eureka Accelerator Program (REAP) grants to BMC, HT, BGK and RA.

Funding bodies played no role in the design of the study, the collection, analysis, and interpretation of data or in writing the manuscript.

Author contributions

RA analyzed and interpreted RNA sequencing data and wrote the manuscript. TH performed the OCMM procedures on the rats. SN and OGS conducted the literature search to identify neurological disorders associated with SDE genes. BGK contributed to study design and manuscript preparation. BMC designed the study, participated in interpreting the results and in writing the manuscript. All authors reviewed and approved the manuscript.

Acknowledgement

Saikumar Karyala at the Virginia Tech sequencing center for RNA sequencing.
Teaching and Research Animal Care Support Services (TRACSS) for day-to-day care and housing of experimental animals.

References

1. World Population Ageing 2019 United Nations, Department of Economic and Social Affairs, Population Division. (2020), 2019 Contract No.: ST/ESA/SER.A/444.
2. Dementia: J 3, 2020; 2020 [updated June 3, 2020; cited 2020 June 3, 2020]. June 3, 2020:[Available from: https://www.who.int/news-room/fact-sheets/detail/dementia.
3. 2020 Alzheimer's disease facts and figures. Alzheimers, Association, Alzheimers A; 2020.
4. Li S-M, Mo M-S, Xu P-Y. Progress in mechanisms of acetylcholinesterase inhibitors and memantine for the treatment of Alzheimer's disease. Neuroimmunol Neuroinflammation. 2015;2(4):274–80.
5. Olivares D, K Deshpande V, Shi Y, K Lahiri D, Greig H, Rogers NT. J, et al. N-methyl D-aspartate (NMDA) receptor antagonists and memantine treatment for Alzheimer's disease, vascular dementia and Parkinson's disease. Curr Alzheimer Res. 2012;9(6):746–58.
6. Mehta M, Adem A, Sabbagh M. New acetylcholinesterase inhibitors for Alzheimer's disease. International Journal of Alzheimer's disease. 2012;2012.
7. Hogan DB. Long-term efficacy and toxicity of cholinesterase inhibitors in the treatment of Alzheimer disease. The Canadian Journal of Psychiatry. 2014;59(12):618–23.
8. Knight R, Khondoker M, Magill N, Stewart R, Landau S. A systematic review and meta-analysis of the effectiveness of acetylcholinesterase inhibitors and memantine in treating the cognitive symptoms of dementia. Dement Geriatr Cogn Disord. 2018;45(3-4):131–51.

9. Kavirajan H, Schneider LS. Efficacy and adverse effects of cholinesterase inhibitors and memantine in vascular dementia: a meta-analysis of randomised controlled trials. Lancet Neurol. 2007;6(9):782–92.

10. Castro-Sánchez AM, Matarán-Peñarrocha GA, Sánchez-Labraca N, Quesada-Rubio JM, Granero-Molina J, Moreno-Lorenzo C. A randomized controlled trial investigating the effects of craniosacral therapy on pain and heart rate variability in fibromyalgia patients. Clinical rehabilitation. 2011;25(1):25–35.

11. García GC, Moreno-Lorenzo C. Influence of Craniosacral Therapy on Anxiety, Depression and Quality of Life in Patients with Fibromyalgia. Evidence-Based Complementary Alternative Medicine. 2011;178769:9.

12. Nourbakhsh MR, Fearon FJ. The effect of oscillating-energy manual therapy on lateral epicondylitis: a randomized, placebo-control, double-blinded study. J Hand Ther. 2008;21(1):4–14.

13. Gerdner LA, Hart LK, Zimmerman MB. Craniosacral still point technique: exploring its effects in individuals with dementia. Journal of Gerontological Nursing. 2008;34(3):36–45.

14. Raviv G, Shefi S, Nizani D, Achiron A. Effect of craniosacral therapy on lower urinary tract signs and symptoms in multiple sclerosis. Complement Ther Clin Pract. 2009;15(2):72–5.

15. Tamburella F, Piras F, Piras F, Spanò B, Tramontano M, Gili T. Cerebral perfusion changes after osteopathic manipulative treatment: a randomized manual placebo-controlled trial. Frontiers in physiology. 2019;10:403.

16. Sergueef N, Nelson KE, Glonek T. The effect of cranial manipulation on the Traube-Hering-Mayer oscillation as measured by laser-Doppler flowmetry. Altern Ther Health Med. 2002;8(6):74.

17. Shi X, Rehrer S, Prajapati P, Stoll ST, Gamber RG, Fred Downey H. Effect of cranial osteopathic manipulative medicine on cerebral tissue oxygenation. J Am Osteopath Assoc. 2011;111(12):660.

18. Martins WR, Diniz LR, Blaszczyk JC, Lagoa KF, Thomaz S, Rodrigues ME, et al. Immediate changes in electroencephalography activity in individuals with nonspecific chronic low back pain after cranial osteopathic manipulative treatment: study protocol of a randomized, controlled crossover trial. BMC Complement Altern Med. 2015;15(1):223.

19. Tobey H, Lucas T, Bledsoe D, Mykins M, Campbell C, Berr SS, et al. Effect of Osteopathic Cranial Manipulative Medicine on an Aged Rat Model of Alzheimer Disease. J Am Osteopath Assoc. 2019;119(11):713.

20. Tobey H, Lucas T, Paul S, Berr SS, Mehrkens B, Brolinson PG, et al. Mechanoeceutics Alters Alzheimer’s Disease Phenotypes in Transgenic Rats: A Pilot Study. Journal of Alzheimer’s Disease. 2020; (Preprint):1–7.

21. Gaub BM, Kasuba KC, Mace E, Strittmatter T, Laskowski PR, Geissler SA, et al. Neurons differentiate magnitude and location of mechanical stimuli. Proceedings of the National Academy of Sciences.
22. Esfandiari L, Paff M, Tang WC. Initial studies of mechanical compression on neurogenesis with neonatal neural stem cells. Nanomed Nanotechnol Biol Med. 2012;8(4):415–8.

23. Chen L-J, Wang Y-J, Chen J-R, Tseng G-F. NMDA receptor triggered molecular cascade underlies compression-induced rapid dendritic spine plasticity in cortical neurons. Exp Neurol. 2015;266:86–98.

24. Mammoto A, Mammoto T, Ingber DE. Mechanosensitive mechanisms in transcriptional regulation. Journal of cell science. 2012;125(13):3061–73.

25. Fabregat A, Sidiropoulos K, Garapati P, Gillespie M, Hausmann K, Haw R, et al. The Reactome pathway Knowledgebase. Nucleic Acids Res. 2016;44(D1):D481-7. PubMed PMID: Medline:26656494.

26. Okuda T, Osawa C, Yamada H, Hayashi K, Nishikawa S, Ushio T, et al. Transmembrane topology and oligomeric structure of the high-affinity choline transporter. J Biol Chem. 2012;287(51):42826–34.

27. Ribeiro FM, Black SA, Prado VF, Rylett RJ, Ferguson SS, Prado MA. The “ins” and “outs” of the high-affinity choline transporter CHT1. Journal of neurochemistry. 2006;97(1):1–12.

28. Bazalakova M, Blakely R. The high-affinity choline transporter: a critical protein for sustaining cholinergic signaling as revealed in studies of genetically altered mice. Neurotransmitter transporters: Springer; 2006. pp. 525–44.

29. Kim A-R, Rylett RJ, Shilton BH. Substrate binding and catalytic mechanism of human choline acetyltransferase. Biochemistry. 2006;45(49):14621–31.

30. Eiden LE, Schäfer MK-H, Weihe E, Schütz B. The vesicular amine transporter family (SLC18): amine/proton antiporters required for vesicular accumulation and regulated exocytotic secretion of monoamines and acetylcholine. Pflügers Archiv. 2004;447(5):636–40.

31. Theis A-K, Rózsa B, Katona G, Schmitz D, Johenning FW. Voltage Gated Calcium Channel activation by backpropagating action potentials downregulates NMDAR function. Frontiers in cellular neuroscience. 2018;12:109.

32. Lacinová L, Klugbauer N. Modulation of gating currents of the Cav3.1 calcium channel by α2δ2a and γ5 subunits. Arch Biochem Biophys. 2004;425(2):207–13.

33. Dessauer CW, Tesmer JJ, Sprang SR, Gilman AG. Identification of a Gia binding site on type V adenylyl cyclase. J Biol Chem. 1998;273(40):25831–9.

34. Posadas I, López-Hernández B, Ceña V. Nicotinic receptors in neurodegeneration. Current neuropharmacology. 2013;11(3):298–314.

35. Mehta M, Adem A, Kahlon MS, Sabbagh MN. The nicotinic acetylcholine receptor: smoking and Alzheimer's disease revisited. Front Biosci. 2012;4:169.

36. Tregellas JR, Wylie KP. Alpha7 nicotinic receptors as therapeutic targets in schizophrenia. Nicotine Tobacco Research. 2019;21(3):349–56.
37. Bissette G, Seidler F, Nemeroff C, Slotkin T. High Affinity Choline Transporter Status in Alzheimer's Disease Tissue from Rapid Autopsy a. Ann N Y Acad Sci. 1996;777(1):197–204.

38. Mubumbila V, Sutter A, Ptok U, Heun R, Quirin-Stricker C. Identification of a single nucleotide polymorphism in the choline acetyltransferase gene associated with Alzheimer's disease. Neurosci Lett. 2002;333(1):9–12.

39. Gao L, Zhang Y, Deng J, Yu W, Yu Y. Polymorphisms of CHAT but not TFAM or VR22 are Associated with Alzheimer Disease Risk. Medical science monitor: international medical journal of experimental clinical research. 2016;22:1924.

40. Muenter MD, Forno LS, Hornykiewicz O, Kish SJ, Maraganore DM, Caselli RJ, et al. Hereditary form of parkinsonism—dementia. Ann Neurol. 1998;43(6):768–81.

41. Karson CN, Casanova MF, Kleinman JE, Griffin WS. Choline acetyltransferase in schizophrenia. The American journal of psychiatry. 1993.

42. Aran A, Segel R, Kaneshige K, Gulsuner S, Renbaum P, Oliphant S, et al. Vesicular acetylcholine transporter defect underlies devastating congenital myasthenia syndrome. Neurology. 2017;88(11):1021–8.

43. Mazère J, Prunier C, Barret O, Guyot M, Hommet C, Guilloteau D, et al. In vivo SPECT imaging of vesicular acetylcholine transporter using [123I]-IBVM in early Alzheimer's disease. Neuroimage. 2008;40(1):280–8.

44. Pippucci T, Parmeggiani A, Palombo F, Maresca A, Angius A, Crisponi L, et al. A novel null homozygous mutation confirms CACNA2D2 as a gene mutated in epileptic encephalopathy. PloS one. 2013;8(12).

45. Chang FC, Westenberger A, Dale RC, Smith M, Pall HS, Perez-Dueñas B, et al. Phenotypic insights into ADCY5-associated disease. Mov Disord. 2016;31(7):1033–40.

46. Trapnell C, Roberts A, Goff L, Pertea G, Kim D, Kelley DR. Differential gene and transcript expression analysis of RNA-seq experiments with TopHat and Cufflinks. Nat Protoc. 2012;7. doi:10.1038/nprot.2012.016.

**Figures**
Figure 1

Significant differentially expressed (SDE) gene pathways. (a) Volcano plot identifying the 246 SDE genes with FDR < 0.004, p-value < 6E-5, t-test, N=3 OCMM treated and 3 untreated rats. (b) Distribution of pathways associated with all genes and SDE genes. Total can be > 100% because genes can be associated with multiple pathways. ***FDR=3E-14, p-value=1E-15 **FDR < 5E-5, p-value<6E-6 *FDR < 0.01, p-value<0.001, chi-squared test, N=14278 all genes and 426 SDE genes. (c) Thirty six of the 426 SDE genes are in neuronal system pathways.

Figure 2
The top five over-expressed genes, CHT1, CHAT, VAcH, CaCN and Adcy5, in the neuronal pathway are part of the acetylcholine (ACh) neurotransmission mechanism. (1) The high affinity choline (Ch) transporter CHT2 transports Ch into the presynaptic terminal. (2) The choline acetylase Chat catalyzes the synthesis of ACh from Ch and acetyl-Coenzyme-A. (3) The vesicular ACh transporter transports ACh into secretory vesicles. (4) Neuronal action potential opens the voltage gated calcium channel (CaCN). Ca ions promote the secretion of Ach into the synaptic cleft. (5) ACh binding to ACh receptors (AChR) on the post synaptic terminal, promotes the release of the Gα subunit of the G-protein complex from the GPCR. Gα can promote or inhibit the cAMP pathway (depending on the type of Gα protein) by binding to Adenylate Cyclase 5, Adcy5. Acetylcholinesterase (AChE) breaks down ACh so Ch can be recycled.
Forty percent of the 426 SDE genes were associated with neurological disorders. * Genes discussed in the text.

Supplementary Files
This is a list of supplementary files associated with this preprint. Click to download.

- tables2.xlsx
- tables1.xlsx